



Review Article

Pharmacogenomics of Pediatric Oncology: Genetic Predictors of Chemotherapy Toxicity in Children

Stella Ehi Egege¹, Micheal Abimbola Oladosu^{2*}, Moses Adondua Abah³, Bukola Oluwaseyi Olufosoye⁴ and Chinwe Dolly Udeka⁵

¹Department of Pharmacological Sciences, Faculty of Medical Sciences, The University of the Health Sciences, St. Kitts, West Indies

²Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.

³Department of Biochemistry, Faculty of Pure and Applied Sciences, Federal University of Wukari, Wukari, Taraba State, Nigeria

⁴Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria

⁵Department of Pharmacy Technician, Faculty of Pharmaceutical Sciences, Mbash College of Health Sciences and Technology, Abia State, Nigeria

*Corresponding Author

Received: Apr 20, 2026/ Revised: June 2026/Accepted: June 3, 2026

Abstract

Chemotherapy-induced toxicity remains a significant challenge in pediatric oncology, affecting treatment outcomes, quality of life, and long-term survival. Inter-individual variability in drug response is partly explained by genetic polymorphisms affecting drug metabolism, transport, and pharmacodynamics. This review examines recent advances in pharmacogenomics of chemotherapy-induced toxicity in pediatric cancer patients, focusing on genetic predictors of serious adverse reactions to commonly used anticancer agents. A comprehensive literature review was conducted examining pharmacogenomic studies published between 2020-2025, focusing on validated genetic markers associated with chemotherapy toxicity in pediatric populations. Significant progress has been made in identifying genetic variants that predict toxicity to thiopurines (TPMT, NUDT15), anthracyclines (SLC28A3, RARG, CBR2), vincristine (CEP72, ABCC1, SLC5A7), and platinum-based agents (ACYP2, TPMT). These variants influence drug metabolism, transport, and cellular sensitivity through various mechanisms. Meta-analyses and large international cohorts have validated several associations, with some achieving clinical implementation. Pharmacogenomic testing offers promise for personalized chemotherapy dosing in pediatric oncology. However, challenges remain regarding clinical implementation, standardization of phenotyping, and the need for validation across diverse populations. Future research should focus on multi-gene risk prediction models and integration into clinical decision-making tools.

Keywords: *Novel drug delivery systems, nanoparticles, smart delivery, stimuli-responsive, personalized medicine, bioavailability, targeted therapy*

1. Introduction

The remarkable improvement in pediatric cancer survival rates over the past five decades, now exceeding 85% for many malignancies, represents one of the most significant

achievements in modern medicine [1]. This success has been largely driven by risk-stratified treatment protocols employing intensive multi-agent chemotherapy regimens. However, the use of highly cytotoxic agents at maximum tolerated doses comes at a considerable cost, with the

majority of pediatric cancer survivors experiencing at least one serious treatment-related toxicity during therapy, and many developing long-term complications that significantly impact quality of life [2,3]

Chemotherapy-induced toxicities in children are particularly concerning due to several factors unique to the pediatric population. Developing organ systems may be more susceptible to damage, toxic effects can impair growth and development, and survivors face decades of potential long-term sequelae. Additionally, the inability of young children to reliably report subjective symptoms complicates early detection and management of toxicities such as peripheral neuropathy and ototoxicity [4]

Substantial inter-individual variability exists in susceptibility to chemotherapy-induced adverse effects, even among children receiving identical treatment protocols. While clinical factors such as age, cumulative drug dose, and concomitant therapies contribute to this variability, germline genetic variation has emerged as a critical determinant of individual risk [5] Pharmacogenomics, the study of how genetic variation influences drug response, offers an opportunity to identify patients at highest risk for serious toxicities before treatment initiation, enabling personalized dose modifications or alternative therapeutic strategies [6].

This review examines the current state of pharmacogenomics in predicting chemotherapy-induced toxicity in pediatric oncology, focusing on genetic markers with robust evidence from recent studies (2020-2025). We discuss validated associations for major drug classes including thiopurines, anthracyclines, vinca alkaloids, and platinum-based agents, and evaluate progress toward clinical implementation of pharmacogenomic testing.

2. Pharmacogenomics Of Thiopurine Toxicity

2.1 Thiopurine Agents in Pediatric Cancer

Thiopurine drugs, including mercaptopurine (6-MP), azathioprine, and thioguanine, are essential components of treatment protocols for acute lymphoblastic leukemia (ALL), which accounts for approximately 25% of pediatric malignancies [7]. During the maintenance phase of ALL therapy, which extends 2-3 years, thiopurines represent the backbone of treatment. However, severe myelosuppression, hepatotoxicity, and gastrointestinal toxicities necessitate dose reductions or treatment interruptions in a significant

proportion of patients, potentially compromising therapeutic efficacy [8].

2.2 TPMT Pharmacogenetics

Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs, representing a major pathway of drug inactivation. Genetic polymorphisms in TPMT resulting in decreased or absent enzyme activity have been recognized as clinically actionable pharmacogenetic markers for over two decades [9]. The most common variant alleles (3A, 3B, 3C, and 2) occur with varying frequencies across ethnic populations, being more prevalent in individuals of European ancestry (5-10%) compared to Asian populations (1-3%) [10].

The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides evidence-based guidelines for TPMT genotype-directed thiopurine dosing. Patients with homozygous variant genotypes (poor metabolizers) require dose reductions of 85-90%, while heterozygous carriers (intermediate metabolizers) typically require 30-70% dose reductions to prevent life-threatening myelosuppression [11].

2.3 NUDT15 Pharmacogenetics

The discovery of NUDT15 (Nudix Hydrolase 15) as a major determinant of thiopurine tolerance in 2014 represented a breakthrough in explaining thiopurine intolerance in East Asian populations where TPMT variants are relatively rare [12]. The most common variant allele, NUDT15*3 (rs116855232, c.415C>T, p.R139C), occurs at significantly higher frequencies in Asian populations (10-20%) compared to European or African populations (<1%) [13].

Recent studies have demonstrated additive effects of TPMT and NUDT15 variants on thiopurine toxicity. A large international study across multiethnic pediatric ALL cohorts demonstrated that patients with compound intermediate metabolizer status (TPMT IM/NUDT15 IM) required greater dose reductions than single IM patients, highlighting the importance of considering both genes in clinical decision-making [14]. Updated CPIC guidelines now incorporate both TPMT and NUDT15 genotyping to optimize thiopurine dosing across diverse populations [15]. Table 1 presents the Major Pharmacogenomic Markers for Thiopurine-Induced Toxicity.

Table 1. Major Pharmacogenomic Markers for Thiopurine-Induced Toxicity

| Gene | Major Variant Alleles | Frequency (Population) | Clinical Impact | CPIC Recommendation |
|---------------|---|--|--|--|
| TPMT | *3A (rs1800460 + rs1142345) *3B (rs1800460) *3C (rs1142345) *2 (rs1800462) | 5-10% (European) 1-3% (Asian) | Severe myelosuppression, hepatotoxicity | IM: 30-70% dose reduction PM: 85-90% dose reduction |
| NUDT15 | *3 (rs116855232) c.415C>T (p.R139C) | 10-20% (East Asian) <1% (European, African) | Severe myelosuppression, hair loss, infections | IM: 50-70% dose reduction PM: 90% dose reduction |
| TPMT + NUDT15 | Compound IM/IM genotype | 1.2% (multiethnic cohorts) | Additive risk - more severe toxicity | Greater dose reduction required (median 25.7 mg/m ²) |

Abbreviations: CPIC, Clinical Pharmacogenetics Implementation Consortium; IM, intermediate metabolizer; PM, poor metabolizer.

Source: Data compiled from references [9, 10, 11, 12, 14].

2.4 Additional Genetic Markers

Beyond TPMT and NUDT15, several candidate genes have been investigated for associations with thiopurine toxicity. Variants in ITPA (inosine triphosphate pyrophosphatase), IL6, and CRIM1 have shown associations with myelosuppression in specific cohorts, though these require validation in larger, independent populations before clinical implementation [16,17]. Recent whole-exome sequencing studies suggest that interplay between multiple genetic variants may better explain toxicity risk in patients with wild-type TPMT and NUDT15 [18].

2. Anthracycline-Induced Cardiotoxicity

3.1 Clinical Significance

Anthracyclines, including doxorubicin, daunorubicin, and epirubicin, are critical components of treatment protocols for leukemias, lymphomas, and solid tumors in children. However, anthracycline-induced cardiotoxicity (AIC) remains a major dose-limiting toxicity, affecting 10-16% of pediatric patients and potentially manifesting decades after treatment completion [19]. The irreversible nature of anthracycline cardiomyopathy and its impact on long-term survival and quality of life underscore the critical need for risk prediction strategies [20].

3.2 SLC28A3 and Drug Transport

The most robustly replicated pharmacogenomic association with AIC involves variants in SLC28A3 (solute carrier

family 28 member 3), which encodes a concentrative nucleoside transporter. A genome-wide association study followed by multi-center replication identified the synonymous variant rs7853758 (c.1383T>G, p.L461L) as protective against anthracycline-induced cardiac dysfunction, with an odds ratio of approximately 0.3-0.4 across multiple pediatric cohorts [21]. This protective effect appears to be mediated through altered expression of a nearby long non-coding RNA (SLC28A3-AS1) rather than changes in the SLC28A3 protein sequence [22].

Recent mechanistic studies using patient-derived induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) have validated the cardioprotective role of this locus and identified potential therapeutic interventions, including the tricyclic antidepressant desipramine, which mimics the protective genetic effect [23].

3.3 RARG and Retinoic Acid Signalling

A candidate gene study identified rs2229774 in RARG (retinoic acid receptor gamma) as significantly associated with increased risk of AIC in children [24]. This variant results in an amino acid substitution (p.Ser427Leu) in the ligand-binding domain of the receptor. Functional studies suggest that the variant allele may alter cellular response to oxidative stress and apoptotic signalling triggered by anthracyclines [25]. Table 2 shows the Pharmacogenetic Markers in Anthracycline-Induced Cardiotoxicity

Table 2. Pharmacogenetic Markers in Anthracycline-Induced Cardiotoxicity

| Gene | Variant | Function | Effect on Risk | Replication Status |
|----------------------|--------------------------------|--|-------------------------|--|
| SLC28A3 | rs7853758 (c.1383T>G, p.L461L) | Nucleoside transporter | OR 0.3-0.4 (protective) | Multiple independent pediatric cohorts; strongest evidence |
| RARG | rs2229774 (p.Ser427Leu) | Retinoic acid receptor gamma | Increased risk | Replicated in multiple cohorts; functional validation |
| CBR3 | Multiple variants | Carbonyl reductase (anthracycline metabolism) | Variable | Inconsistent across studies; requires further validation |
| CELF4 | rs1786814 | RNA-binding protein (cardiac biology) | Dose-dependent | Replicated; effect >300 mg/m ² cumulative dose |
| GSTM1 | Null deletion | Glutathione S-transferase (antioxidant defense) | Increased risk | Replicated in multiple pediatric cohorts |
| SULT2B1 ABCB4 | Multiple variants | Sulfotransferase (SULT2B1); Drug transporter (ABCB4) | Sex-specific effects | SULT2B1 in males; ABCB4 in females |

Abbreviations: OR, odds ratio.

Sources: Data compiled from references [21, 22, 23, 24, 25, 26, 27].

3.4 Additional Genetic Determinants

Multiple candidate gene studies have identified associations with variants in genes involved in anthracycline metabolism (CBR3, CBR1), antioxidant defense (GSTM1), and cardiac biology (CELF4, HAS3) [26]. A recent systematic review

identified CBR2, CELF4, GSTM1, HAS3, RARG, and SLC28A3 as genes with replicated associations in pediatric cohorts [27]. However, sex-specific effects have been noted for several variants, including SULT2B1 (males) and ABCB4 (females), suggesting complex gene-environment interactions [27]. Figure 1 shows the Mechanisms of Anthracycline-Induced Cardiotoxicity and Pharmacogenetic Modifiers.

4. Vincristine-Induced Peripheral Neuropathy

4.1 Clinical Impact

Vincristine, a microtubule-disrupting vinca alkaloid, is used in treatment protocols for ALL, lymphomas, neuroblastoma, and various solid tumors. Vincristine-induced peripheral neuropathy (VIPN) occurs in 30-78% of treated children, manifesting as sensory loss, motor weakness, and neuropathic pain [28]. Severe VIPN necessitates dose reductions or treatment delays, potentially compromising disease control. Unlike many chemotherapy toxicities, VIPN

can persist for years after treatment completion, significantly impacting quality of life [29].

4.2 CEP72 Polymorphisms

The landmark genome-wide association study by Diouf et al. identified rs924607 in the promoter region of CEP72 (centrosomal protein 72) as significantly associated with VIPN risk [30]. The variant T allele results in decreased CEP72 expression, which sensitizes neurons to vincristine-induced damage. Functional studies demonstrated that reduced CEP72 expression compromises microtubule formation through mechanisms distinct from vincristine, essentially "lowering the threshold" for vincristine neurotoxicity [31].

This association has been replicated in multiple independent cohorts, with meta-analyses confirming odds ratios of 2-3.5 for the risk genotype [32,33]. However, the association appears most robust in patients receiving prolonged vincristine therapy during continuation treatment, with less consistent findings during induction therapy, suggesting time-dependent or cumulative dose-dependent effects [34].

4.3 Drug Transport Genes

Variants in ATP-binding cassette (ABC) transporters have shown associations with VIPN. A Canadian pharmacogenomics study identified ABCC1 rs3784867 as significantly associated with VIPN (OR 4.9), suggesting that altered vincristine efflux from neurons may modify toxicity risk[35]. Additionally, SLC5A7, which is involved in choline transport and has connections to hereditary neuropathies, showed strong association with VIPN (OR 8.6) [35]




Figure 1: Mechanisms of Anthracycline-Induced Cardiotoxicity and Pharmacogenetic Modifiers
 Sources: Adapted from references [21,24,26,27]

Table 2. Genetic Variants Associated with Vincristine-Induced Peripheral Neuropathy

| Gene | Variant (rsID) | Effect/Location | Odds Ratio (95% CI) | Proposed Mechanism |
|--------|-----------------------|-----------------|---------------------------------|--|
| CEP72 | rs924607 (T allele) | Promoter region | 2.0-3.5 (meta-analysis) | Decreased CEP72 expression sensitizes neurons to vincristine; impaired microtubule formation |
| ABCC1 | rs3784867 | Coding region | 4.9 (2.0-12.1) | Altered vincristine efflux from neurons |
| SLC5A7 | rs1013940 | Intronic | 8.6 (1.9-39.8) | Choline transport; linked to hereditary neuropathies |
| NRG3 | Novel variants (GWAS) | Multiple loci | HR 0.36 (protective) | Neuregulin signaling; neuronal protection |
| ACTN1 | Novel variants (GWAS) | Multiple loci | Protective (combined with NRG3) | Alpha-actinin; cytoskeletal organization |

Abbreviations: CI, confidence interval; GWAS, genome-wide association study; HR, hazard ratio. Data compiled from references [30, 31, 32, 33, 34, 35, 36].

4.4 Novel GWAS Findings

A recent genome-wide association study in over 1,100 pediatric patients identified 13 novel genomic variants associated with VIPN risk or protection [36]. Notably, protective variants in *NRG3* (neuregulin 3) and *ACTN1* (alpha-actinin 1) showed additive effects, with patients carrying both variants experiencing substantially reduced

neuropathy incidence (HR 0.36). These findings highlight the complexity of VIPN genetics and suggest that multiple biological pathways contribute to individual susceptibility [36]. Figure 2 presents the Schematic representation of genetic variants affecting Vincristine Pharmacokinetics and Pharmacodynamics in Peripheral Neuropathy.




Figure 2: Schematic representation of genetic variants affecting Vincristine Pharmacokinetics and Pharmacodynamics in Peripheral Neuropathy.

Sources: Adapted from references [30,32,35,36]

5. Platinum-Induced Ototoxicity

5.1 Cisplatin Ototoxicity

Platinum-based agents, particularly cisplatin, are essential for treating medulloblastoma, neuroblastoma, osteosarcoma, and germ cell tumors. Cisplatin-induced ototoxicity affects 40-70% of pediatric patients, manifesting as irreversible, bilateral, high-frequency sensorineural hearing loss [37]. In young children, hearing impairment during critical developmental periods can profoundly affect language acquisition, academic performance, and social development [38].

5.2 ACYP2 Polymorphisms

The ACYP2 (acylphosphatase 2) gene emerged from genome-wide association studies as a robust predictor of cisplatin ototoxicity across both pediatric and adult populations. The variant rs1872328 has been associated with significantly increased ototoxicity risk in multiple independent cohorts [39]. While the precise mechanism remains unclear, ACYP2 is expressed in cochlear tissues and may influence cellular response to cisplatin-induced damage.

Recent meta-analyses have confirmed consistent associations (OR 3.9-5.9) across diverse populations [40,41].

5.3 Controversial TPMT and COMT Associations

Early candidate gene studies reported strong associations between variants in TPMT (rs12201199) and COMT (rs9332377, rs4646316) with cisplatin ototoxicity in children [42]. However, subsequent replication attempts have yielded inconsistent results, with some large studies failing to confirm these associations [43,44]. A 2023 systematic review by the Canadian Pharmacogenomics Network for Drug Safety concluded that while ACYP2 shows consistent association with ototoxicity, the evidence for TPMT remains controversial and may be population-specific or confounded by concurrent therapies [45].

5.4 Additional Genetic Factors

Variants in genes associated with Mendelian hearing loss syndromes, including *WFS1*, have shown associations with cisplatin ototoxicity, suggesting that baseline genetic predisposition to auditory dysfunction may modify drug-induced hearing damage [46]. Additionally, variants in drug transport genes (*SLC22A2/OCT2*) and DNA repair genes (*ERCC2*, *XPC*, *GSTP1*) have been implicated, though

require validation in adequately powered cohorts [47,48]. Figure 3 shows the Schematic illustration of the Major

Pharmacogenomic variants and Chemotherapy toxicities.




Figure 3: A Schematic illustration of the Major Pharmacogenomic variants and Chemotherapy toxicities. Sources: Authors illustration compiled from references [11,14,21,32,40]

6. Clinical Implementation and Challenges

6.1 Current State of Clinical Implementation

Despite substantial pharmacogenomic evidence, clinical implementation remains limited. TPMT genotyping prior to thiopurine therapy represents one of the few widely adopted pharmacogenetic tests in pediatric oncology, with many centers routinely testing patients before initiating mercaptopurine [49]. The recent addition of NUDT15 to CPIC guidelines has prompted expanded testing panels, particularly in centers serving diverse patient populations [50].

Preemptive pharmacogenomic testing panels that include TPMT, NUDT15, and other actionable variants are being piloted at several major pediatric cancer centers. Cost-effectiveness analyses suggest that combined TPMT/NUDT15 testing provides substantial cost savings by preventing severe myelosuppression and associated hospitalizations [51].

6.2 Barriers to Implementation

Several challenges impede broader clinical adoption of pharmacogenomics in pediatric oncology. First, inconsistency in study results, often due to small sample sizes, heterogeneous phenotype definitions, and population differences, limits confidence in many gene-drug associations. Second, for most toxicities, no validated multi-gene risk prediction models exist that integrate genetic and

clinical risk factors. Third, the actionability of genetic information varies considerably—while dose adjustments are well-established for TPMT/NUDT15, appropriate interventions for other genetic risks remain unclear. Finally, implementation requires integration of genetic testing into clinical workflows, development of clinical decision support tools, and education of healthcare providers [52].

6.3 Ethical Considerations

Pharmacogenomic testing in pediatric populations raises unique ethical considerations. Since most genetic variants represent germline polymorphisms, testing generates information with potential implications beyond cancer therapy. Parents and patients should be informed about the scope and limitations of testing, including uncertainty in risk prediction and limited options for risk mitigation for many variants. Additionally, equitable access to testing and concerns about health disparities must be addressed, as many pharmacogenomic studies have been conducted primarily in populations of European ancestry [53].

7. Future Directions

7.1 Multi-Gene Risk Models

Future research should focus on developing and validating multi-gene risk prediction models that integrate multiple genetic variants with clinical risk factors. Machine learning approaches may prove useful in identifying complex gene-gene and gene-environment interactions. Recent studies have

demonstrated proof-of-concept for multi-marker models predicting anthracycline cardiotoxicity and thiopurine myelosuppression [54].

7.2 Functional Validation

Mechanistic understanding of genetic associations through functional studies is essential for moving beyond statistical associations to biological understanding. Patient-derived induced pluripotent stem cells, CRISPR-based gene editing, and other emerging technologies offer powerful tools for validating and characterizing genetic variants [23]. Such functional validation can inform therapeutic strategies, as demonstrated by the identification of desipramine as a potential cardioprotective agent based on SLC28A3 pharmacogenomics [23].

7.3 Implementation Science

Research is needed to develop effective strategies for implementing pharmacogenomic testing in routine clinical practice. This includes developing clinical decision support tools, establishing standardized protocols for result interpretation and clinical action, and demonstrating clinical utility and cost-effectiveness. Collaborative efforts such as the implementing GeNomics In pracTicE (IGNITE) network are addressing these challenges [55].

7.4 Health Disparities

Most pharmacogenomic studies have been conducted in populations of European ancestry, limiting generalizability to other populations. Substantial differences in allele frequencies across populations are well-documented for TPMT, NUDT15, and other pharmacogenes. Future studies must include diverse populations to ensure equitable benefit from precision medicine approaches. Additionally, research is needed to understand how genetic ancestry interacts with social determinants of health in influencing treatment outcomes [56].

8. Conclusion

Pharmacogenomics holds substantial promise for personalizing cancer therapy in children by identifying those at highest risk for serious treatment-related toxicities. Genetic variants in TPMT and NUDT15 (thiopurine toxicity), SLC28A3 and RARG (anthracycline cardiotoxicity), CEP72 and ABCC1 (vincristine neuropathy), and ACYP2 (cisplatin ototoxicity) have achieved varying levels of validation and clinical implementation. While TPMT genotyping has become standard practice in many centers, implementation of other pharmacogenetic tests remains limited.

Key challenges include the need for larger validation studies in diverse populations, development of multi-gene risk prediction models, demonstration of clinical utility beyond risk prediction, and addressing implementation barriers. As

genomic technologies become more accessible and affordable, integration of preemptive pharmacogenomic testing into routine pediatric oncology care becomes increasingly feasible. Ultimately, the goal is to achieve optimal balance between treatment efficacy and toxicity for each individual patient, maximizing cure rates while minimizing both acute and long-term treatment-related morbidity.

Acknowledgement

The authors sincerely appreciate the valuable contributions of the research team and Writers whose work provided technical support during the writing of this review. Special thanks go to the academic mentors and institutional reviewers for their constructive feedback, which greatly improved the quality of this manuscript. The authors also acknowledge the intellectual support received from colleagues at their respective institutions.

Author Contributions

The author has significantly contributed to the study's conception, design, data collection, analysis, and interpretation. All authors were involved in writing the manuscript or critically reviewing it for its intellectual value. They have reviewed and approved the final version for submission and publication and accept full responsibility for the content and integrity of the work.

Financial Support

The authors declare that no external funding was received for this study.

Conflicts of Interest

The authors state that there are no financial, personal, or professional conflicts of interest associated with this research.

Ethical Approvals

This research did not involve the use of human participants or animal subjects and therefore did not require ethical clearance

Publisher's Note

The Journal stays neutral about jurisdictional claims in published maps and institutional affiliations

References

1. Ramsey LB, Brown JT, Vear SI, et al. Gene-based dose optimization in children. *Annu Rev Pharmacol Toxicol.* 2019;60:311-331. doi:10.1146/annurev-pharmtox-010919-023459

2. Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM. Pharmacogenomics as a tool to limit acute and long-term adverse effects of chemotherapeutics: an update in pediatric oncology. *Front Pharmacol.* 2020;11:1184. doi:10.3389/fphar.2020.01184
3. Kager L, Evans WE. Pharmacogenomics in pediatric oncology research and treatment. *J Pediatr Pharmacol Ther.* 2024;29(5):554-557. doi:10.5863/1551-6776-29.5.554
4. Reizine NM, O'Donnell PH. Modern developments in germline pharmacogenomics for oncology prescribing. *CA Cancer J Clin.* 2022;72(4):315-332. doi:10.3322/caac.21722
5. Hansson P, Blacker C, Uvdal H, et al. Pharmacogenomics in pediatric oncology patients with solid tumors related to chemotherapy-induced toxicity: a systematic review. *Crit Rev Oncol Hematol.* 2025;211:104720. doi:10.1016/j.critrevonc.2025.104720
6. Maggo S, Pan Y, Ostrow D, et al. Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing. *Front Genet.* 2025;16:1574325. doi:10.3389/fgene.2025.1574325
7. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? *Blood.* 2012;120(6):1165-1174. doi:10.1182/blood-2012-05-378943
8. Mao X, Yin R, Sun G, et al. Effects of TPMT, NUDT15, and ITPA genetic variants on 6-mercaptopurine toxicity for pediatric patients with acute lymphoblastic leukemia in Yunnan of China. *Front Pediatr.* 2021;9:719803. doi:10.3389/fped.2021.719803
9. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther.* 2011;89(3):387-391. doi:10.1038/clpt.2010.320
10. Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. *Nat Genet.* 2014;46(9):1017-1020. doi:10.1038/ng.3060
11. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. *Clin Pharmacol Ther.* 2019;105(5):1095-1105. doi:10.1002/cpt.1304
12. Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. *J Clin Oncol.* 2015;33(11):1235-1242. doi:10.1200/JCO.2014.59.4671
13. Lee JM, Shim YJ, Kim DH, Jung N, Ha JS. The effect of NUDT15, TPMT, APEX1, and ITPA genetic variations on mercaptopurine treatment of pediatric acute lymphoblastic leukemia. *Children (Basel).* 2021;8(3):224. doi:10.3390/children8030224
14. Maillard M, Nishii R, Yang W, et al. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations. *J Natl Cancer Inst.* 2024;116(5):702-710. doi:10.1093/jnci/djae004
15. Gammal RS, Pirmohamed M, Somogyi AA, et al. Expanded clinical pharmacogenetics implementation consortium guideline for medication use in the context of G6PD genotype. *Clin Pharmacol Ther.* 2023;113(5):973-985. doi:10.1002/cpt.2821
16. Lee YH, Song GG. Association between IL6 polymorphisms and susceptibility to thiopurine-induced leukopenia: a meta-analysis. *Genet Test Mol Biomarkers.* 2021;25(4):234-241. doi:10.1089/gtmb.2020.0329
17. Ali AM, Adam H, Hailu D, et al. Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. *Front Pharmacol.* 2023;14:1159307. doi:10.3389/fphar.2023.1159307
18. Kim Y, Goh H, Lee SY, et al. Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT. *Sci Rep.* 2021;11:10063. doi:10.1038/s41598-021-88963-5
19. Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol.* 2015;16(3):e123-e136. doi:10.1016/S1470-2045(14)70409-7
20. Chaix MA, Parmar N, Kinnear C, et al. Machine learning identifies clinical and genetic factors associated with anthracycline cardiotoxicity in pediatric cancer survivors. *JACC CardioOncol.* 2020;2(5):690-706. doi:10.1016/j.jacc.2020.11.004
21. Visscher H, Rassekh SR, Sandor GS, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J Clin Oncol.* 2012;30(13):1422-1428. doi:10.1200/JCO.2010.34.3467
22. Magdy T, Ackerman MJ, Pottinger TD, et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. *Circulation.* 2022;145(4):279-294. doi:10.1161/CIRCULATIONAHA.121.05580
23. Magdy T, Ackerman MJ, Pottinger TD, et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. *Circulation.* 2022;145(4):279-294. doi:10.1161/CIRCULATIONAHA.121.055801
24. Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. *Nat Genet.* 2015;47(9):1079-1084. doi:10.1038/ng.3374
25. Ding Y, Du K, Niu YJ, et al. Genetic susceptibility and mechanisms underlying the pathogenesis of anthracycline-associated cardiotoxicity. *Life Sci.* 2022;307:120873. doi:10.1016/j.lfs.2022.120873
26. Wong LYF, Sutcliffe AG, Ho CLT, et al. Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis. *Front Pharmacol.* 2025;16:1568320. doi:10.3389/fphar.2025.1568320
27. Visscher H, Ross CJ, Rassekh SR, et al; CPNDS Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J Clin Oncol.* 2012;30(13):1422-1428. doi:10.1200/JCO.2010.34.3467
28. Mora E, Smith EML, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy in pediatric cancer patients. *Am J Cancer Res.* 2016;6(11):2416-2430.
29. Smith EML, Kuisell C, Cho Y, et al. Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: a systematic review. *Cancer Treat Res Commun.* 2021;28:100420. doi:10.1016/j.ctarc.2021.100420
30. Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. *JAMA.* 2015;313(8):815-823. doi:10.1001/jama.2015.0894

31. Relling MV, Evans WE. Pharmacogenomics of vincristine-induced peripheral neuropathy: progress continues. *Clin Pharmacol Ther.* 2019;105(2):248-251. doi:10.1002/cpt.1268
32. Uittenboogaard A, Neutel CLG, Ket JCF, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy in children with cancer: a systematic review and meta-analysis. *Cancers (Basel).* 2022;14(3):612. doi:10.3390/cancers14030612
33. Yu Q, Hu Y, Chen F, et al. Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. *Front Pharmacol.* 2021;12:771487. doi:10.3389/fphar.2021.771487
34. Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. *Pharmacogenet Genomics.* 2016;26(2):100-102. doi:10.1097/FPC.0000000000000191
35. Wright GEB, Amstutz U, Drögemöller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. *Clin Pharmacol Ther.* 2019;105(2):402-410. doi:10.1002/cpt.1179
36. Nguyen JQ, Ramsey LB, Nishii R, et al. Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patients. *NPJ Genom Med.* 2024;9(1):56. doi:10.1038/s41525-024-00443-7
37. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. *J Clin Oncol.* 2012;30(19):2408-2417. doi:10.1200/JCO.2011.39.1110
38. Clemens E, de Vries AC, Pluijm SF, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. *Eur J Cancer.* 2016;69:77-85. doi:10.1016/j.ejca.2016.09.023
39. Yang JJ, Lim JY, Huang J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. *Clin Pharmacol Ther.* 2013;94(2):252-259. doi:10.1038/clpt.2013.121
40. Clemens E, Broer L, Langer T, et al. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: the International PanCareLIFE study. *Pharmacogenomics J.* 2020;20(2):294-305. doi:10.1038/s41397-019-0113-1
41. Thiesen S, Yin P, Jorgensen AL, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. *Pharmacogenet Genomics.* 2017;27(6):213-222. doi:10.1097/FPC.0000000000000281
42. Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. *Nat Genet.* 2009;41(12):1345-1349. doi:10.1038/ng.478
43. Yang JJ, Lim JY, Huang J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. *Clin Pharmacol Ther.* 2013;94(2):252-259. doi:10.1038/clpt.2013.121
44. Hagleitner MM, Coenen MJ, Patino-Garcia A, et al. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. *PLoS One.* 2014;9(12):e115869. doi:10.1371/journal.pone.0115869
45. Loeffen EAH, Kremer LCM, Mulder RL, et al. Systematic critical review of genetic factors associated with cisplatin-induced ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 update. *Clin Pharmacol Ther.* 2023;114(6):1183-1198. doi:10.1002/cpt.3050
46. Wheeler HE, Gamazon ER, Frisina RD, et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. *Clin Cancer Res.* 2017;23(13):3325-3333. doi:10.1158/1078-0432.CCR-16-2809
47. Lanvers-Kaminsky C, Sprowl JA, Malath I, et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. *Pharmacogenomics.* 2015;16(4):323-332. doi:10.2217/pgs.14.182
48. Clemens E, Broer L, Langer T, et al. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: the International PanCareLIFE study. *Pharmacogenomics J.* 2020;20(2):294-305. doi:10.1038/s41397-019-0113-1
49. Chenchula S, Atal S, Uppugunduri CRS. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. *Pharmacogenomics J.* 2024;24(2):9. doi:10.1038/s41397-024-00326-1
50. Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPgx guidelines. *Front Pharmacol.* 2021;11:595219. doi:10.3389/fphar.2020.595219
51. Fuerte B, Burgos M, Cao V, et al. Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients. *Pharmacogenet Genomics.* 2025;35(2):73-80. doi:10.1097/FPC.0000000000000550
52. Relling MV, Evans WE. Pharmacogenomics in the clinic. *Nature.* 2015;526(7573):343-350. doi:10.1038/nature15817
53. Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature.* 2016;538(7624):161-164. doi:10.1038/538161a
54. Chaix MA, Parmar N, Kinnear C, et al. Machine learning identifies clinical and genetic factors associated with anthracycline cardiotoxicity in pediatric cancer survivors. *JACC CardioOncol.* 2020;2(5):690-706. doi:10.1016/j.jacc.2020.11.004

55. Levy KD, Blake K, Fletcher-Hoppe C, et al. Opportunities to implement preemptive pharmacogenetic testing in adults: a systematic review. *Genet Med.* 2022;24(3):543-557. doi:10.1016/j.gim.2021.11.011
56. Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet.* 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x

How to cite this article

Egege, S. E., Oladosu, M. A., Abah, M. A., Olufosoye, B. O., & Udeka, C. D. (2026). *Pharmacogenomics of pediatric oncology: Genetic predictors of chemotherapy toxicity in children.* *Science Archives*, 7(2), 181–191. <https://doi.org/10.47587/SA.2026.7217>

This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/)

